HC Wainwright Predicts Stronger Earnings for Prime Medicine

Prime Medicine, Inc. (NYSE:PRME) – Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Prime Medicine in a research report issued on Wednesday, March 4th. HC Wainwright analyst A. He now expects that the company will earn ($0.28) per share for the quarter, up from their previous estimate of ($0.33). The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($1.19) EPS, FY2028 earnings at ($1.01) EPS, FY2029 earnings at ($0.82) EPS and FY2030 earnings at ($0.62) EPS.

A number of other equities research analysts have also recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Prime Medicine in a report on Monday, November 10th. Lifesci Capital started coverage on shares of Prime Medicine in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $6.00 price target on the stock. Citigroup decreased their price objective on shares of Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Finally, Chardan Capital dropped their target price on shares of Prime Medicine from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.21.

Prime Medicine Trading Down 4.6%

NYSE:PRME opened at $3.93 on Friday. The stock has a market capitalization of $709.41 million, a P/E ratio of -1.92 and a beta of 2.56. Prime Medicine has a 1 year low of $1.11 and a 1 year high of $6.94. The firm has a 50 day moving average of $3.82 and a 200-day moving average of $4.17.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Creative Planning acquired a new stake in shares of Prime Medicine during the 2nd quarter worth approximately $25,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Prime Medicine in the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in Prime Medicine during the 4th quarter worth $33,000. Glen Eagle Advisors LLC bought a new stake in shares of Prime Medicine during the 4th quarter valued at $35,000. Finally, Savant Capital LLC acquired a new stake in shares of Prime Medicine during the second quarter worth $37,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.

Prime Medicine News Roundup

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Lifesci Capital reiterated an “Outperform” rating with a $6.00 price target and modeled FY2026 EPS of ($0.90), notably less negative than the current consensus of ($1.68), suggesting expected improvement in the company’s loss profile. Lifesci Capital estimates and rating
• Positive Sentiment: An analyst-consensus summary showed Prime Medicine has an average analyst rating of “Moderate Buy,” which can attract buying interest from funds and retail investors. Prime Medicine receives average “Moderate Buy”
• Neutral Sentiment: Lifesci published granular quarterly EPS forecasts (Q4 2025 and each quarter of 2026 at ~$ (0.23) per quarter) that give investors a clearer guidance baseline for modeling cash needs and runway but don’t change near-term operations. Detailed quarterly EPS estimates
• Negative Sentiment: Despite the upbeat ratings, forecasts still show the company remaining unprofitable next year (negative EPS), underscoring execution and funding risk for a clinical-stage biotech; this keeps downside risk if pipeline progress or financing plans disappoint. Consensus earnings context

About Prime Medicine

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.